Brazil health regulator Anvisa on Wednesday allowed resumption of late-stage Brazilian clinical trials for China's Sinovac SVA.O COVID-19 vaccine, which had been suspended due to a study subject's death that was registered in Sao Paulo as a http://suicide.t.rs/3lsBOow
-
Show this thread
0 replies
1 retweet
5 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.